

References

I-181

1. Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial. *Br J Haematol*. 2016;172(4):535-544.
2. Duvic M, Kim YH, Zinzani PL, et al. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. *Clin Cancer Res*. 2017;23(14):3552-3556.
3. Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. 2018;131(4):397-407.
4. Kelly KR, Gabrail N, Weitman S, et al. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. *Cancer Chemother Pharmacol*. 2016;78(5):929-939.
5. Pralatrexate In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 1, 2010.
6. Clinical PharmacologyTM Compendium 2024. Tampa FL: Gold Standard, Inc. Pralatrexate.
7. Micromedex DrugDex Compendium[®]. 2024. Pralatrexate.
8. National Comprehensive Cancer Network (NCCN). Pralatrexate. NCCN Drugs and Biologics Compendium[®]. 2024.
9. Folutyn (pralatrexate), injection for intravenous use [package insert]. Acrotech Biopharma LLC. East Windsor, NJ. Revised 09/2020.